VIENNA, Austria, Dec. 21, 2023 (GLOBE NEWSWIRE) -- invIOs GmbH (invIOs), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week...
Multi-center trial of novel autologous cell therapy APN401 leveraging two GMP-compliant manufacturing sites has received regulatory approval and patient recruitment has started;invIOs awarded up to...
INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indicationsTreatment with INV501 significantly inhibits tumor...
invIOs to present at Biotech Showcase
VIENNA, Austria, Nov. 10, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today presented data from the ongoing clinical trial of its APN401 cell therapy at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022) in Boston, MA. The patient case report shows that a heavily pre-treated patient with metastatic appendix carcinoma achieved stable disease over the course of 27 weeks of treatment with invIOs’s Cbl-b silenced cell therapy.
VIENNA, Austria, Oct. 18, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that two abstracts on its clinical stage lead program, APN401, have been accepted for poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022) being held in Boston, MA, on November 8-12, 2022.
VIENNA, Austria, Oct. 11, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces its participation at three upcoming industry and investor conferences: BIO-Europe, Inv€$tival Showcase and the Jefferies 2022 London Healthcare Conference.